The recommended dosage of anlotinib is 12 mg once daily, to be administered orally on an empty stomach (no food should be consumed 2 hours before and after medication). The treatment cycle consists of continuous administration for 14 days followed by a 7-day drug holiday, forming a 21-day cycle. The specific dosage must be strictly followed as per the physician’s instructions and adjusted based on the patient’s individual condition.
Recommended Dosage and Treatment Cycle
Standard Regimen
The recommended dose is 12 mg per day, to be taken on an empty stomach either before breakfast or 2 hours after a meal.
Treatment Cycle: Continuous administration for 14 consecutive days, followed by a 7-day withdrawal period, with 21 days constituting a complete treatment cycle.
Treatment should be continued until disease progression or the occurrence of intolerable toxic reactions.
Dose Adjustment
Dose Reduction Indications: In case of severe adverse reactions (e.g., hypertension, proteinuria, hemorrhage, etc.), the dose may be reduced to 10 mg or 8 mg per day.
Discontinuation Criteria: Permanent drug withdrawal is required if the adverse reactions remain intolerable after dose adjustment.
Precautions
Individualized Treatment
For patients with abnormal liver/kidney function, advanced age, or complicated with other diseases, dosage adjustment must be made after evaluation by a physician.
Routine monitoring of indicators such as blood pressure, urine routine, and coagulation function is required during the medication period.
Adverse Reaction Management
Common adverse reactions include fatigue, hypertension, hand-foot syndrome, etc., for which symptomatic treatment should be administered as needed.
Immediate drug withdrawal and medical attention are imperative if life-threatening adverse reactions occur, such as hemoptysis or severe gastrointestinal bleeding.
Medication Tips
Strictly Follow Physician’s Instructions
Anlotinib is a prescription-only medicine. Self-adjustment of dosage or administration frequency is prohibited.
Drug Interactions
Avoid concurrent use with anticoagulants or other anti-angiogenic agents, as this may increase the risk of hemorrhage.
Special Populations
Contraindicated in pregnant women, lactating women, and patients with a history of active hemorrhage.
If anlotinib treatment is required, please consult the oncology department or relevant specialist clinics of a regular hospital. A personalized treatment plan will be formulated by the physician based on the pathological type, disease progression, and physical condition of the patient. Under no circumstances should the drug be used without medical supervision.
